Background Cystic fibrosis (CF) care has been implemented in Turkey for a long time; however, there had been no patient registry. For this purpose, the Turkish National CF Registry was established. We present the first results of registry using data collected in 2017. Methods The data were collected using a data‐entry software system, which was accessed from the internet. Demographic and annually recorded data consisted of 15 and 79 variables, respectively. Results There were 1170 patients registered from 23 centers; the estimated coverage rate was 30%. The median age at diagnosis was 1.7 years (median current age: 7.3 years); 51 (4.6%) patients were aged over 18 years. Among 293 patients who were under 3 years of age, 240 patients (81.9%) were diagnosed through newborn screening. Meconium ileus was detected in 65 (5.5%) patients. Genotyping was performed in 978 (87.4%) patients and 246 (25.2%) patients' mutations were unidentified. The most common mutation was deltaF508 with an allelic frequency of 28%, followed by N1303K (4.9%). The median FEV1% predicted was 86. Chronic colonization with Pseudomonas aeruginosa was seen in 245 patients. The most common complication was pseudo‐Bartter syndrome in 120 patients. The median age of death was 13.5 years in a total of 15 patients. Conclusions Low coverage rate, lack of genotyping, unidentified mutations, and missing data of lung functions are some of our greatest challenges. Including data of all centers and reducing missing data will provide more accurate data and help to improve the CF care in Turkey in the future.
Pollen concentrations in the atmosphere of Istanbul, a city located between two continents, has been monitored for 1 year as part of a larger research program. The sampling sites were located in two different continents: the Asian part (AS) and the European part (EP). The sampling was performed in AS and EP of the city by using Hirst type volumetric method, and pollen grains of 58 and 62 taxa were identified in the two parts, respectively. The pollen spectrum reflected the floristic diversity of the region. The main pollen producers at the sites were characterized by some allergenic pollen and were identified as Cupressaceae/Taxaceae, Urticaceae, Pistacia sp., Quercus sp., Platanus sp., Fraxinus sp., and Xanthium sp. These pollen types contributed to the total pollen sum with a percentage of more than 80% at both monitoring sites. The highest amount of pollen grains was recorded in April. The greatest number of species was recorded in May, when 42 types (AS) and 44 types (EP) were present.
Tuberculosis is an important health problem in developing countries and the BCG vaccine plays an important part in preventing the disease. There are different reports about the preventive value of BCG. Some of them claim that it is satisfactory while others suggest that it provides little protection. There are also varying ideas about the optimum time to vaccinate babies, some studies suggesting that late vaccination confers a high degree of protection. This prospective controlied study has been undertaken to evaluate the value of BCG vaccine given to babies during their first three days of life versus its value when given in their third month of life. Evaluation was measured by the results of tests with purified protein derivative (PPD), by vaccine scars, and by the complications of the vaccine. It was found that BCG given at the end of the third month provides a higher rate of response and fewer complications than when given during the first three days of life.BCG plays a significant part in protection against tuberculosis, which is one of the most important problems in developing countries. Nevertheless, the protective effect of vaccine remains a highly controversial subject, and has been reported to range from 80% to less than 5%. '4 In many countries the first BCG vaccine is received at birth, but it has been suggested that this requires further evaluation.' 7 8 A controlled prospective study has been recommended' 7 to compare BCG results from vaccination at birth and those at the third month of life. This prospective controlled study was planned to compare tuberculin response, BCG scar, and the complications of the vaccine given in the first three days compared with the third month of life. Subjects and methods The subjects selected for the study were healthy, full term babies of over 2500 g born either in the Uludag University Medical School Hospital or City Maternity Hospital in Bursa between October 1989 and January 1990. All the babies were followed up to 12 months. Babies who had a history of tuberculosis among their family or close contacts were excluded from the study.Babies were randomly divided into two groups. Four hundred babies in the first group (group I) were vaccinated with BCG intradermally in the left shoulder in the first three days of life, and the second group of 400 babies (group II) was vaccinated in the same manner at the end of the third month (90±3 days) of life. Vaccines were given to both groups by the same trained personnel. At the beginning of the study the mothers of the babies under study were carefully examined and their BCG scars and induration of purified protein derivative (PPD) were recorded. For the babies in group II, a PPD test was carried out before the BCG vaccination. The babies in both groups were examined every three months until they were 12 months old, PPD tests were performed three months after BCG vaccination and at the end of the first year. A full examination was performed in the follow up and BCG complications were recorded. Lymphadenopathies of mo...
BackgroundPseudo‐Bartter syndrome (PBS) is a rare complication of cystic fibrosis (CF) and there are limited data in the literature about it. We aimed to compare clinical features and accompanying findings of patients with PBS in a large patient population.MethodsThe data were collected from the Cystic Fibrosis Registry of Turkey where 1170 CF patients were recorded in 2017. Clinical features, diagnostic test results, colonization status, complications, and genetic test results were compared in patients with and without PBS.ResultsTotally 1170 patients were recorded into the registry in 2017 and 120 (10%) of them had PBS. The mean age of diagnosis and current age of patients were significantly younger and newborn screening positivity was lower in patients with PBS (P < .001). There were no differences between the groups in terms of colonization status, mean z‐scores of weight, height, BMI, and mean FEV1 percentage. Types of genetic mutations did not differ between the two groups. Accompanying complications were more frequent in patients without PBS.ConclusionPBS was detected as the most common complication in the registry. It could be due to warm weather conditions of our country. It is usually seen in younger ages regardless of mutation phenotype and it could be a clue for early diagnosis of CF.
In order to determine the asthma prevalence in 6-12-year-old schoolchildren in Istanbul, we issued 2350 questionnaires, according to ISAAC criteria, in six randomly selected city primary schools to be completed at home by parents. A total of 2232 of the questionnaires were completed, an overall response rate of 94.9%, and 2216 questionnaires were taken into consideration. The prevalence of asthma was found to be 9.8% and wheezing 15.1%. To investigate the effect of socioeconomic status on the prevalence of asthma, we evaluated the heating system at home, the place of residence, the educational levels of the mother and father, the number of people living in the house, the sharing of bedrooms, and the annual family income. In conclusion, the prevalence of childhood asthma was not affected by any of these factors. Atopic family history, food allergy, eczema, and frequent otitis media and sinusitis attacks were evaluated and found to be significant in asthma prevalence.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.